<DOC>
	<DOCNO>NCT01465243</DOCNO>
	<brief_summary>To determine whether dose escalation provide good survival patient fail icotinib routine dose .</brief_summary>
	<brief_title>Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose</brief_title>
	<detailed_description>Lung cancer major cause morbidity mortality , rapidest increase type cancer China 5 time incidence rate increase past 30 year . Tyrosine kinase inhibitor ( TKIs ) epidermal growth factor receptor ( EGFR ) widely use treatment patient non-small cell lung cancer ( NSCLC ) . Icotinib novel EGFR-TKI develop group Chinese scientist clinician . Icotinib appear non-inferior Gefitinib term efficacy , good term safety , large therapeutic window phase I-III trial . In study , open , single-center , single arm phase IV trial design evaluate safety efficacy dose escalation icotinib treatment advance NSCLC patient failure routine dose . PFS ( progress free survival ) primary end-point OS ( overall survival ) , ORR ( objective response ) , TTP ( time progress ) , HRQOL safety secondary end-point .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Confirmed NSCLC Histology cytology ; advanced ï¼ˆIIIb/IV ) . 2 . Must receive 1 2 chemotherapy ( least 1 platin base ) , prior chemotherapy must complete least 4 week study enrollment . 3 . Measurable , evaluable disease outside radiation port . 1 . Previous usage EGFRTKI antibody EGFR : gefitinib , erlotinib , herceptin , erbitux . 2 . Other coexist malignancy malignancy diagnose within last 5 year exception basal cell carcinoma cervical cancer situ .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Efficacy</keyword>
	<keyword>Safety</keyword>
	<keyword>EGFR-TKI</keyword>
	<keyword>phase IV</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Dose escalation</keyword>
</DOC>